Trial Profile
A Multi-center, Open-label, Non-randomized, Phase I Dose Escalation Study of Regorafenib (BAY 73-4506) in Pediatric Subjects With Solid Malignant Tumors That Are Recurrent or Refractory to Standard Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Irinotecan; Vincristine
- Indications Adenocarcinoma; Adrenal cancer; Astrocytoma; CNS cancer; Colon cancer; Ependymoma; Ewing's sarcoma; Glioblastoma; Glioma; Haemangioendothelioma; Hepatoblastoma; Medulloblastoma; Neuroblastoma; Oligodendroglioma; Osteosarcoma; Primitive neuroectodermal tumours; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer; Bayer HealthCare
- 19 Apr 2024 Status changed from active, no longer recruiting to completed.
- 19 Oct 2023 Planned End Date changed from 28 Dec 2024 to 31 Mar 2024.
- 22 Aug 2023 Results(n=21, median age 10 years) published in the Clinical Cancer Research